Etanercept: An overview - 29/08/11
Abstract |
Etanercept, a competitive inhibitor of TNF-⍺, is currently FDA approved for psoriatic arthritis and rheumatoid arthritis. The molecular structure of etanercept, its mechanism of action, and results of clinical trials involving patients with psoriasis will be reviewed.
Le texte complet de cet article est disponible en PDF.Plan
Funding sources: None. Disclosure: Drs Cather and Goffe have participated in clinical trials involving Enbrel. Dr Goffe is involved in trials funded by Immunex (now Amgen), Biogen, Genentech, Corixa, IDEC, Boehringer-Ingelheim, ISIS, Fujisawa, and Bristol Meyers. Dr Goffe is on the speaker’s bureau for Amgen; however, he is not a paid consultant. |
Vol 49 - N° 2S
P. 105-111 - août 2003 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?